A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2011
10/06/2011	WO2011122524A1 Controlled release pharmaceutical composition
10/06/2011	WO2011122523A1 Controlled release pharmaceutical composition
10/06/2011	WO2011122458A1 Aromatic ring compound containing nitrogen
10/06/2011	WO2011121354A1 The therapeutic use of tetrathiomolybdate
10/06/2011	WO2011121308A1 New polymorph
10/06/2011	WO2011120604A1 "trpv1 vanilloid receptor antagonists with a bicyclic portion"
10/06/2011	WO2011120118A1 Method for preparing matrix micro-particles of copaífera langsdorffii (aerial parts) and for isolating the active principles therein; thus prepared analgesic, anti-spasmodic, anti-inflammatory, diuretic and antiseptic micro-particles and compounds with anti-lithiasis activity (renal calculi), formulations, products and uses thereof
10/06/2011	WO2011035110A3 Treatment for oxidative stress and/or hypertension
10/06/2011	US20110245297 Use Quaternary Pyridinium Salts as Vasoprotective Agents
10/06/2011	US20110245294 Methods of improving quality of sleep
10/06/2011	US20110245265 Cxcr4 antagonists for kidney injury
10/06/2011	US20110245251 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
10/06/2011	US20110245248 Isoquinoline derivatives
10/06/2011	US20110245227 Pyridone gpr119 g protein-coupled receptor agonists
10/06/2011	US20110245169 Protection, restoration and enhancement of erythropoietin responsive cells, tissues and organs
10/06/2011	US20110244064 composition for the treatment of hypertension
10/06/2011	US20110244051 Pharmaceutical formulations for the treatment of overactive bladder
10/06/2011	US20110244033 Tamsulosin pellets for fixed dose combination
10/06/2011	US20110243990 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
10/06/2011	US20110243943 Treatment using relaxin-fusion proteins with extended in vivo half-lives
10/06/2011	US20110243936 TNFalpha-NEUTRALIZING ANTIBODIES
10/06/2011	US20110243924 Novel methods
10/06/2011	US20110243923 Organic compounds
10/06/2011	US20110243890 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus
10/06/2011	US20110243889 Opioid and opioid-like compounds and uses thereof
10/06/2011	CA2795400A1 Prevention and treatment of cast nephropathy
10/06/2011	CA2795257A1 Pharmaceutical formulations for the treatment of overactive bladder
10/06/2011	CA2795253A1 Methods of improving quality of sleep
10/06/2011	CA2794773A1 Trpv1 vanilloid receptor antagonists with a bicyclic portion
10/06/2011	CA2794555A1 Improved treatment of renal cell carcinoma
10/05/2011	EP2371958A1 Novel siRNAs and methods of use thereof
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2369945A2 Companion animal compositions including lipoic acid and methods of use thereof
10/05/2011	EP1812002B1 Treatment of mastitis
10/05/2011	EP1501830B1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
10/05/2011	EP1463497B1 Treating muscle wasting with selective androgen receptor modulators
10/05/2011	EP1230209B3 Stable salts of novel derivatives of 3,3-diphenylpropylamines
10/05/2011	CN1817883B New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
10/05/2011	CN1446227B Novel fibroblast growth factor (FRF23) and method for use
10/05/2011	CN102209718A Carbamate compound or salt thereof
10/05/2011	CN102206277A Antibodies that bind human interleukin-18 and methods of making and using
10/05/2011	CN102205043A Chinese herbal medicine preparation for treating prostatic swelling or hypertrophy in middle-aged and elderly people
10/05/2011	CN102205009A Traditional Chinese medicine for treating urinary tract stones
10/05/2011	CN102205005A Chinese medicinal preparation for treating diabetic nephropathy
10/05/2011	CN102204997A Scindapsus aureus extract for treating diabetic nephropathy and preparation method and application thereof
10/05/2011	CN102204995A Kidney-reinforcing tonic wine
10/05/2011	CN102204948A Novel application of alchornea trewioides extract in pharmacy
10/05/2011	CN102204939A Method for preparing pomegranate peel polyphenol liposome by reverse evaporation method
10/05/2011	CN102204889A Degarelix acetate lyophilized powder injection and preparation method thereof
10/05/2011	CN101856450B Chinese medicinal composition for treating diabetic nephropathy
10/05/2011	CN101829259B Footbath effervescent tablet for improving prostatitis
10/05/2011	CN101757298B Process for extracting and purifying tianschanica maxim total flavonoid
10/05/2011	CN101732323B Application of low-dose ursolic acid as medicament for treating diabetic early nephropathy
10/05/2011	CN101700340B Oral traditional Chinese medicine composition for treating chronic nephritis
10/05/2011	CN101618123B Medicated wine for supplementing qi and strengthening kidney
10/05/2011	CN101505766B Preventive remedial therapeutic agent for phosphorus impairment, oral agent for adsorbing phosphate ion contained in food, beverage and chemical, and process for producing them
10/05/2011	CN101466371B Stabilized pharmaceutical compositions comprising fesoterodine
10/05/2011	CN101301392B Chinese medicine for treating systemic lupus erythematosus and preparation thereof
10/05/2011	CN101297880B Active extract containing phlorizin and uses thereof
10/04/2011	USRE42802 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
10/04/2011	US8030517 CCR9 inhibitors and methods of use thereof
10/04/2011	US8030502 Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects
10/04/2011	US8030489 Ornithine derivative
10/04/2011	US8030310 Therapeutic agents useful for treating pain
10/04/2011	US8030275 Methods for treating obesity using fibroblast growth factor-like polypeptides
10/04/2011	CA2673462C Solid oral dosage forms of valsartan
10/04/2011	CA2491079C Therapeutic piperazine derivatives useful for treating pain
10/04/2011	CA2438520C Phthalazinone-piperidino-derivatives as pde4 inhibitors
10/04/2011	CA2371839C Hydroxymatairesinol in cancer prevention
09/2011
09/29/2011	WO2011086507A8 "compositions comprising amino acids for prevention and/or treatment of renal disorders"
09/29/2011	WO2011053860A3 Mesenchymal stromal cell populations and methods of using same
09/29/2011	US20110237783 Hydrazonopyrazole derivatives and their use as therapeutics
09/29/2011	US20110237659 Chromenone derivatives as trpv3 antagonists
09/29/2011	US20110237651 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
09/29/2011	US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
09/29/2011	US20110237649 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
09/29/2011	US20110237648 Rna interference in skin indications
09/29/2011	US20110237639 Imidazolinylmethyl aryl sulfonamide
09/29/2011	US20110237633 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
09/29/2011	US20110237622 Renin inhibitors
09/29/2011	US20110237607 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
09/29/2011	US20110237518 Method for treating or preventing bladder cancer using the depdc1 polypeptide
09/29/2011	US20110237513 Ltbp2 as a biomarker for renal dysfunction
09/29/2011	US20110236994 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
09/29/2011	US20110236505 Carbohydrate bar
09/29/2011	US20110236438 Method of treatment of diseases using hoodia extracts
09/29/2011	US20110236436 Pharmaceutical composition for modified release
09/29/2011	US20110236397 Limited proteolysis of cd2ap and progression of renal disease
09/29/2011	US20110236360 Lactic acid bacterium having high oxalic acid decomposition ability
09/29/2011	US20110236352 PEGylation by the Dock and Lock (DNL) Technique
09/29/2011	US20110236340 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
09/29/2011	US20110236317 Tetrahydrotriazine compounds for treating diseases associated with ampk acitivity
09/28/2011	EP2368910A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
09/28/2011	EP2368876A1 Derivatives of aminoindanes, their preparation and their application in therapeutics
09/28/2011	EP2367426A1 Phenazopyridine compounds
09/28/2011	EP2133335B1 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
09/28/2011	EP1643999B1 Pyridoxamine for use in the treatment of diabetic neprhopathy in type ii diabetes
09/28/2011	EP1426054B1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
09/28/2011	EP1421191B1 Humanised antibodies specific for both CD45RB and CD45RO
09/28/2011	EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors

1 ... 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 ... 562